Broad Institute & Calico Collaborate
News Mar 24, 2015
The Broad Institute of MIT and Harvard has entered into a partnership with Calico around the biology and genetics of aging and early-stage drug discovery. The partnership will support several efforts at the Broad to advance the understanding of age-related diseases and to propel the translation of these findings into new therapeutics.
Calico is the Google-backed life sciences company led by Arthur D. Levinson, Ph.D. (former Chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech). As part of the collaboration, the Broad Institute will pursue shared goals with Calico by leveraging the Institute's deep genetics and biology expertise and novel drug-discovery tools.
"We are thrilled to be partnering on discovery and therapeutics projects with the extraordinary scientific team at Calico," said Eric Lander, President and Director of the Broad Institute. "The combination of our genetics, biology and chemistry expertise with Calico's therapeutics expertise will accelerate progress on important problems."
"This alliance is a key part of Calico's strategy to bring the best cutting-edge science to bear on problems of aging. The Broad Institute is one of the nation's preeminent research organizations whose outstanding research has repeatedly revealed fundamental mechanisms of the biology and genetics of disease," said Art Levinson, Chief Executive Officer of Calico.
"Broad scientists have led the way in describing the genetics underlying many of the common diseases of aging, including heart disease, diabetes, and cancer, and we look forward to collaborating with them. We are very excited by the opportunity to apply their insights to develop new medicines for patients with these devastating diseases," commented Hal Barron, President of Research and Development at Calico.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018